Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Megan R Reed"'
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/abbd8a9d867a42f9b25418a603a99057
Autor:
Alicja Urbaniak, Megan R. Reed, Billie Heflin, John Gaydos, Sergio Piña-Oviedo, Marta Jędrzejczyk, Greta Klejborowska, Natalia Stępczyńska, Timothy C. Chambers, Alan J. Tackett, Analiz Rodriguez, Adam Huczyński, Robert L. Eoff, Angus M. MacNicol
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 153, Iss , Pp 113440- (2022)
Glioblastoma (GBM) remains the most frequently diagnosed primary malignant brain cancer in adults. Despite recent progress in understanding the biology of GBM, the clinical outcome for patients remains poor, with a median survival of approximately on
Externí odkaz:
https://doaj.org/article/3ff41f2fa16c4f20a3d33e8d6d5030db
Autor:
Megan R. Reed, Annick De Loose, Grace Guzman, A. Geoffrey Lyle, Katrina Learned, Olena M. Vaske, Analiz Rodriguez
Publikováno v:
Journal of Clinical and Translational Science, Vol 7, Pp 95-95 (2023)
OBJECTIVES/GOALS: MGMT methylation status is used to predict the response to TMZ. However, a subpopulation of patients lacking MGMT methylation still respond to TMZ. We applied omics approaches and functional studies to a cohort of GBM patients to id
Externí odkaz:
https://doaj.org/article/7bf4b3824955461aa533092e3e2800e6
Autor:
Alicja Urbaniak, Megan R. Reed, Daniel Fil, Anika Moorjani, Sarah Heflin, Michał Antoszczak, Michał Sulik, Adam Huczyński, Michalina Kupsik, Robert L. Eoff, Melanie C. MacNicol, Timothy C. Chambers, Angus M. MacNicol
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 141, Iss , Pp 111815- (2021)
Breast cancer remains one of the leading cancers among women. Cancer stem cells (CSCs) are tumor-initiating cells which drive progression, metastasis, and reoccurrence of the disease. CSCs are resistant to conventional chemo- and radio-therapies and
Externí odkaz:
https://doaj.org/article/8f0fa178769f44c6a5f9775fcc5dbcfa
Publikováno v:
Brain Research Bulletin. 196:76-98
Autor:
Megan R. Reed, A. Geoffrey Lyle, Annick De Loose, Katrina Learned, Cecile Rose T. Vibat, Christopher P. Wardell, Robert L. Eoff, Olena M. Vaske, Analiz Rodriguez
Publikováno v:
Journal of Clinical and Translational Science, Vol 6, Pp 58-58 (2022)
OBJECTIVES/GOALS: A functional precision medicine platform to identify therapeutic targets for a glioblastoma patient with Li Fraumeni syndrome was performed. Comparative transcriptomics identified druggable targets and patient derived organoids and
Externí odkaz:
https://doaj.org/article/c2c3317ab6de45a186e45d9014a1a342
Publikováno v:
Current Oncology Reports. 25:479-489
Abstract Purpose of Review This review will discuss the challenges facing chimeric antigen receptor (CAR)-T cell application for solid tumors and opportunities to overcome these obstacles. In addition, this review will examine therapies that are in d
Autor:
Megan R. Reed, A. Geoffrey Lyle, Annick De Loose, Leena Maddukuri, Katrina Learned, Holly C. Beale, Ellen T. Kephart, Allison Cheney, Anouk van den Bout, Madison P. Lee, Kelsey N. Hundley, Ashley M. Smith, Teresa M. DesRochers, Cecile Rose T. Vibat, Murat Gokden, Sofie Salama, Christopher P. Wardell, Robert L. Eoff, Olena M. Vaske, Analiz Rodriguez
Publikováno v:
Cells, Vol 10, Iss 12, p 3400 (2021)
Li Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome caused by germline mutations in TP53. TP53 is the most common mutated gene in human cancer, occurring in 30–50% of glioblastomas (GBM). Here, we highlight a precision medicin
Externí odkaz:
https://doaj.org/article/9dc85f09d7834fddbaa84d2a1a8e9843
Publikováno v:
ACS Synth Biol
Clarithromycin is an improved semi-synthetic analogue of the naturally occurring macrolide, erythromycin. The subtle modification of a methyl group on the C-6 hydroxyl group endows the molecule with improved acid stability and results in a clinically
Autor:
Jacob L. Edmondson, Megan R. Reed, Lauren C. Morehead, Billie Heflin, Brian Koss, Alan J. Tackett
Publikováno v:
Cancer Research. 83:LB041-LB041
Unleashing the immune anti-tumor response through immune checkpoint inhibitors (ICIs) is a promising strategy to combat many solid-tumor malignancies, including metastatic melanoma. When successful, the anti-tumor response is potent; however, around